Corey Stephen Cutler, M.D.
This page shows the publications co-authored by Corey Cutler and Nathaniel Treister.
Topical sirolimus for management of refractory oral chronic graft-versus-host disease. Oral Dis. 2020 Oct 10.
Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium. Bone Marrow Transplant. 2013 Aug; 48(8):1123-8.
Oral chronic graft-versus-host disease scoring using the NIH consensus criteria. Biol Blood Marrow Transplant. 2010 Jan; 16(1):108-14.
Use of Prescription Sialagogues for Management of Xerostomia in Chronic Graft-versus-Host-Disease. Transplant Cell Ther. 2021 06; 27(6):480.e1-480.e5.
Long-Term Utilization Patterns of Topical Therapy and Clinical Outcomes of Oral Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2020 02; 26(2):373-379.
Economic and Practical Considerations in the Treatment of Oral Mucosal Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant. 2018 08; 24(8):1748-1753.
An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2016 11; 22(11):2084-2091.
Oral chronic GVHD outcomes and resource utilization: a subanalysis from the chronic GVHD consortium. Oral Dis. 2016 Apr; 22(3):235-40.
Assessing the relationship between oral chronic graft-versus-host disease and global measures of quality of life. Oral Oncol. 2015 Oct; 51(10):944-9.
Mammalian target of rapamycin inhibitor-associated stomatitis in hematopoietic stem cell transplantation patients receiving sirolimus prophylaxis for graft-versus-host disease. Biol Blood Marrow Transplant. 2015 Mar; 21(3):503-8.
How we treat oral chronic graft-versus-host disease. Blood. 2012 Oct 25; 120(17):3407-18.
Medical management update: Non-Hodgkin lymphoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Jan; 107(1):e19-33.
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006 Jul 15; 108(2):756-62.
Oral health in allogeneic hematopoietic stem cells transplantation survivors. Bone Marrow Transplant. 2020 11; 55(11):2211-2214.
Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors. Oral Oncol. 2018 06; 81:1-9.
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015 Mar; 21(3):389-401.e1.
Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011 Dec 01; 365(22):2055-66.
Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006 Apr; 12(4):375-96.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.